Methoxy Polyethylene glycol-epoetin beta Articles
Roche 2009 figures miss targets, hit by Genentech buy costs and slowing sales of some cancer drugs
3 February 2010
Court blocks Roche’s sales of Mircera in USA until 2014, as Amgen prevails in EPO patent dispute
23 December 2009
Roche nine-month 2009 sales boosted by strong Tamiflu showing
15 October 2009
US Appeals Court backs Amgen against Roche’s peg-EPO product
16 September 2009
Japan stock market week to March 30, 2009
31 March 2009
Highlights of first PDCO meeting of 2009
26 January 2009
Pharmaceutical firms cooperate with World Anti-Doping Agency
15 December 2008
Court affirms four Amgen EPO patents
13 October 2008
Roche to appeal US Mircera sales bar
21 April 2008
Roche invests $389M in Germany, Switzerland
28 January 2008
FDA OKs Mircera but ruling delays launch
26 November 2007
Amgen wins in Roche Mircera patent suit
29 October 2007
Japan stock market week to June 4, 2007
11 June 2007
Roche's Mircera gets nod from CHMP
4 June 2007
FDA gives tentative nod to Roche's Mircera
28 May 2007
Stock Commentary - New York week to Mar 12, 2007
26 March 2007
Stock Commentary - New York week to Aug 15
29 January 2007
Roche submits more data for Mircera BLA
22 December 2006
Roche's Mircera is first renal anemia drug to work on a twice-monthly dosing regimen
27 November 2006
US court denies Roche's motion to dismiss Amgen's law suit
30 October 2006
Roche reports sales of $23.89B for first three qtrs of 2006, a 4.7% share of global market
23 October 2006
ITC will not review initial verdict in Roche case
11 September 2006
Split patent decison for Amgen and Shire
14 August 2006
ERA meeting: Roche's Mircera is first drug to convert anemia dialysis patients to once-monthly dosing
24 July 2006
Showing 1-27 of 27 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
